Success Metrics

Clinical Success Rate
100.0%

Based on 5 completed trials

Completion Rate
100%(5/5)
Active Trials
2(22%)
Results Posted
20%(1 trials)

Phase Distribution

Ph phase_3
3
33%
Ph early_phase_1
1
11%
Ph phase_1
2
22%
Ph phase_2
3
33%

Phase Distribution

3

Early Stage

3

Mid Stage

3

Late Stage

Phase Distribution9 total trials
Early Phase 1First-in-human
1(11.1%)
Phase 1Safety & dosage
2(22.2%)
Phase 2Efficacy & side effects
3(33.3%)
Phase 3Large-scale testing
3(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

5 of 5 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

9

all time

Status Distribution
Active(2)
Completed(5)
Other(2)

Detailed Status

Completed5
unknown2
Active, not recruiting1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
2
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Early Phase 11 (11.1%)
Phase 12 (22.2%)
Phase 23 (33.3%)
Phase 33 (33.3%)

Trials by Status

unknown222%
active_not_recruiting111%
recruiting111%
completed556%

Recent Activity

2 active trials
Showing 5 of 9
active_not_recruitingphase_2

Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION)

NCT03775486
completedphase_1

A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors

NCT02009449
recruitingphase_1

A Randomised Trial of Chemotherapy Plus Surgery for Recurrent Non-Small Cell Lung Cancer

NCT02889666
unknownearly_phase_1

Drug Screening Using IMD in Bladder Cancer

NCT06204614
unknownphase_2

Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Carboplatin in Triple Negative Breast Cancer (TNBC)

NCT02341911
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT03775486Phase 2

Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION)

Active Not Recruiting
NCT02009449Phase 1

A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors

Completed
NCT02889666Phase 1

A Randomised Trial of Chemotherapy Plus Surgery for Recurrent Non-Small Cell Lung Cancer

Recruiting
NCT06204614Early Phase 1

Drug Screening Using IMD in Bladder Cancer

Unknown
NCT02341911Phase 2

Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Carboplatin in Triple Negative Breast Cancer (TNBC)

Unknown
NCT01082549Phase 3

Trial of Gemcitabine/Carboplatin With or Without Iniparib (SAR240550) (a PARP1 Inhibitor) in Subjects With Previously Untreated Stage IV Squamous Non-Small-Cell Lung Cancer (NSCLC)

Completed
NCT00874419Phase 3

Erlotinib Versus Gemcitabine/Carboplatin in Chemo-naive Stage IIIB/IV Non-Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Exon 19 or 21 Mutation

Completed
NCT00938652Phase 3

A Phase 3, Multi-Center Study of Gemcitabine/Carboplatin, With or Without BSI-201, in Patients With ER-, PR-, and Her2-Negative Metastatic Breast Cancer

Completed
NCT00540358Phase 2

A Phase 2 Trial of Standard Chemotherapy, With or Without BSI-201, in Patients With Triple Negative Metastatic Breast Cancer

Completed

All 9 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
9